Furthermore, in our study cohorts, we found that PD-L1 expression levels were higher in advanced versus ES-NSCLC in the presence of EGFR, KRAS, and MET exon 14 skipping alterations. The gene discussed is MET; the disease is non-small cell lung carcinoma.